Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246396 · ClinicalTrials.gov registry record · Phase 4
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
A Phase 4 study of Hypertension, Resistant to Conventional Therapy, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06246396 is a Phase 4 study of Hypertension, Resistant to Conventional Therapy that is actively recruiting participants, run by University of Florida. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06246396, a Phase 4 study of Hypertension, Resistant to Conventional Therapy, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Minocycline Hydrochloride
Study Locations (1)
Florida
- UF Clinical Research Center (UF CRC) - CTSI - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2028-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06246396
The ClinicalTrials.gov registry entry for NCT06246396 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension, Resistant to Conventional Therapy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06246396 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06246396 about?
NCT06246396 is a clinical study titled "Antihypertensive Mechanisms of Minocycline in Resistant Hypertension". The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects media...
What is the current status of trial NCT06246396?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2025-01-08. Estimated completion is 2028-07.
What conditions does trial NCT06246396 study?
This clinical trial studies the following conditions: Hypertension, Resistant to Conventional Therapy.
What interventions are being tested in trial NCT06246396?
The interventions under investigation include: Placebo (DRUG), Minocycline Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06246396?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06246396 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension, Resistant to Conventional Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.